Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing

被引:58
作者
Ramos-Arroyo, MA [1 ]
Moreno, S [1 ]
Valiente, A [1 ]
机构
[1] Hosp Virgen Camino, Serv Genet Med, Navarra 31008, Spain
关键词
D O I
10.1136/jnnp.2004.036806
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Prior to the discovery of the Huntington's disease (HD) mutation, the prevalence, incidence, and new mutation rates for this disease were based on the presence of progressive choreic movements and a positive family history. Objective: To evaluate the uptake of the HD genetic analysis in Spain, and to provide additional information on the epidemiology of this disease from the experience of 9 years of direct genetic testing. Methods: From 1994 to 2002, CAG repeat length was determined in 317 patients with symptoms compatible with HID. in all cases, demographic, clinical, and family data were carefully reviewed. Results: HD diagnosis (CAG repeat length greater than or equal to36) was confirmed in 166 (52%) symptomatic cases. Of these, 76 (45.8%) reported a positive family history and in 21 cases (12.7%) family history was negative. New mutation events were genetically proven in three families and highly suspected in another, estimating that the minimum new mutation rate for HID in our population is >4%, with a potential mutation rate of 8%. More than 16% of all HD cases had late onset (>59 years) of symptoms, and in three quarters of these the family history was negative. The incidence rate for the autonomous communities of Navarra and the Basque country, based on the number of newly diagnosed cases by genetic testing, was 4.7 per million per year. Conclusions: Direct HD genetic testing shows that the incidence and mutation rates of the disease are 2-3 times higher than previously reported. We also demonstrated the relevance of CAG repeat length assessment in diagnosing patients with late onset of symptoms and negative family history for HD.
引用
收藏
页码:337 / 342
页数:6
相关论文
共 22 条
[1]   High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia [J].
Almqvist, EW ;
Elterman, DS ;
MacLeod, PM ;
Hayden, MR .
CLINICAL GENETICS, 2001, 60 (03) :198-205
[2]   Rethinking genotype and phenotype correlations in polyglutamine expansion disorders [J].
Andrew, SE ;
Goldberg, YP ;
Hayden, MR .
HUMAN MOLECULAR GENETICS, 1997, 6 (12) :2005-2010
[3]   THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
TELENIUS, H ;
THEILMANN, J ;
ADAM, S ;
STARR, E ;
SQUITIERI, F ;
LIN, BY ;
KALCHMAN, MA ;
GRAHAM, RK ;
HAYDEN, MR .
NATURE GENETICS, 1993, 4 (04) :398-403
[4]  
ANDREW SE, 1994, AM J HUM GENET, V54, P852
[5]  
Burguera JA, 1997, REV NEUROLOGIA, V25, P1845
[6]  
Calcedo Ordonez A, 1970, Rev Clin Esp, V119, P333
[7]  
CONNEALLY PM, 1984, AM J HUM GENET, V36, P506
[8]   Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases [J].
Falush, D ;
Almqvist, EW ;
Brinkmann, RR ;
Iwasa, Y ;
Hayden, MR .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (02) :373-385
[9]   MOLECULAR ANALYSIS OF NEW MUTATIONS FOR HUNTINGTONS-DISEASE - INTERMEDIATE ALLELES AND SEX OF ORIGIN EFFECTS [J].
GOLDBERG, YP ;
KREMER, B ;
ANDREW, SE ;
THEILMANN, J ;
GRAHAM, RK ;
SQUITIERI, F ;
TELENIUS, H ;
ADAM, S ;
SAJOO, A ;
STARR, E ;
HEIBERG, A ;
WOLFF, G ;
HAYDEN, MR .
NATURE GENETICS, 1993, 5 (02) :174-179
[10]  
Harper P.S., 1996, HUNTINGTONS DIS